News Highlights: Top Company News of the Day
U.S. Vaccine Panel Delays Vote on J&J Covid-19 Shot's Clot Risk
The federal government's recommendation to pause using Johnson
& Johnson's Covid-19 vaccine will remain in place after an
advisory panel put off a vote on how to move forward following
reports of a few cases of life-threatening blood clots.
Dell Plans Spinoff of $52 Billion Stake in VMware
The personal-computer maker said it intends to use net proceeds
from the deal to pay down debt.
Dell CFO Looks to Use VMware Proceeds to Bring Down Debt
"This accelerates our plan to delever the company," Chief
Financial Officer Tom Sweet said.
Thermo Fisher Nears Deal to Buy PPD for More Than $15 Billion
If completed, deal would be the latest tie-up among companies
that run clinical trials and provide other services for
Novavax to Participate in Oxford Study Comparing Covid-19 Vaccine Combinations
A Novavax Covid-19 vaccine will be studied in a Phase 2 trial
conducted by the University of Oxford "to evaluate the potential
for combined regimens that mix vaccines from different
manufacturers to achieve immune protection against Covid-19."
Coinbase Fetches $85 Billion in Value in Trading Debut
The cryptocurrency exchange is the first major bitcoin-focused
company to test the U.S. public market, marking a watershed moment
for an industry that began a decade ago as an experiment in digital
American-JetBlue Alliance Draws Increased Scrutiny From DOJ
The Justice Department has stepped up an antitrust probe of
American Airlines's recent partnership with JetBlue Airways,
concerned the deal could lead to anticompetitive coordination and
inflated fares at certain hubs.
Qantas Ramping Up Domestic Capacity Amid Leisure Surge
Australia's No. 1 airline, Qantas Airways Ltd., said it is
increasing domestic capacity faster than expected in response to a
surge in demand from leisure travelers as coronavirus restrictions
EU Orders Extra Pfizer Vaccines Amid J&J Suspension
The European Union, grappling with the potential loss of Johnson
& Johnson Covid-19 vaccines, will buy an additional 50 million
doses from BioNTech and Pfizer for the quarter, and is in talks to
purchase up to 1.8 billion more doses over the next two years.
Bed Bath & Beyond's Improvement Project Is Far From Finished
The selloff in Bed Bath & Beyond looks overdone considering
its unsurprising results, but the retailer still has a way to go to
win back confidence.
(END) Dow Jones Newswires
April 15, 2021 01:00 ET (05:00 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.